Organogenesis (ORGO)
Develops regenerative products for advanced wound care, surgery, and sports medicine.
Something off on this page? Send us feedback.
Sells regenerative-medicine products for advanced wound care and a smaller surgical and sports-medicine portfolio through one reportable segment. Sales lean heavily toward wound care, with execution shaped by FDA-cleared or approved products, reimbursement rules, and manufacturing transitions.
Develops and manufactures regenerative-medicine products for Advanced Wound Care and Surgical & Sports Medicine. Advanced Wound Care includes brands such as Apligraf and PuraPly; the surgical line includes NuShield, Cygnus Matrix, PuraForce, Affinity, and Novachor.
Based in Canton, Massachusetts, with employees worldwide, the business sells into hospitals, wound care centers, government facilities, ambulatory surgery centers, and physician offices. Advanced Wound Care is sold mainly through direct sales representatives; Surgical & Sports Medicine relies mainly on third-party agencies.
Execution depends on regulated biologic and device products, reimbursement coverage, and wound-care demand. Dermagraft manufacturing and distribution remain suspended pending the Smithfield, Rhode Island facility transition.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | Target: $3 | Target: $2 |
| May 28, 2026 | UBS | Target | Target: — | Target: $3 |
| May 28, 2026 | Truist Financial | Target | Target: — | Target: $3 |
| Nov 20, 2025 | BTIG | Reiterate | Rating: —Target: — | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $46.1M · Total debt $67.0M · Total assets $406.4M · Shareholders' equity $288.1M
- Revenue
- $43.8M
- Operating income
- −$51.0M
- Net income
- −$99.3M
No dividends on record.
| Institutions | ≈ 51.97% | 66.88M shares | |
|---|---|---|---|
| 137 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 111.13% | 143.00M shares | |
| 17 holders · as of Apr 24, 2026 | |||
| Strategic holders | 47.80% | 61.50M shares | |
| 3 holders · as of Dec 2, 2024 | |||
| Adds to | 210.90% | ||
128.67M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 210.90%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alan A. Ades1Insiderdirector, 10 percent owner | 41.25% | 22.32M · 30.75M | filed Jun 26, 2025 |
Albert EraniInsider10 percent owner | 40.09% | 51.59M | filed Nov 14, 2024 |
GN 2016 Family Trust u/a/d August 12, 2016Strategic10 percent owner | 39.70% | 51.09M | filed Dec 2, 2024 |
Thompson DeanInsider | 22.29% | 28.68M | filed Nov 19, 2024 |
Morgan StanleyInstitution | 9.11% | 11.72M | as of Jun 30, 2026 |
- Alan A. Ades's own ownership statement (13D, Jun 26, 2025) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph Driscoll | director | +10,000 | $2.67 |
| Mar 9, 2026 | Arthur S. Leibowitz | director | +5,000 | $2.68 |
| Dec 16, 2025 | Glenn H. Nussdorf | director | −200,000 | $5.14 |
| Nov 26, 2025 | Glenn H. Nussdorf | director, 10 percent owner: | −187,957 | $5.29 |
| Nov 25, 2025 | Glenn H. Nussdorf | director, 10 percent owner: | −12,043 | $5.30 |
- MiMedx
Placental allograft rival in wound and surgical biologics
- Integra LifeSciences
Dermal matrices and wound reconstruction rival
- Smith & Nephew (ADR)
Global wound and sports-medicine platform rival
- Solventum
Large NPWT and advanced-dressings rival
- AVITA Medical
Acute-wound cell therapy and matrix rival
- TELA Bio
Soft-tissue reinforcement specialist rival
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Organogenesis | $1.44 | −2.37% | $190.4M | — | — | 0.4 | −56.7% |
| MiMedx | $4.83 | −2.13% | $718.6M | 123.2 | 48.6 | 2.0 | −34.7% |
| Integra LifeSciences | $15.75 | −1.72% | $1.25B | — | 6.2 | 0.8 | +0.8% |
| Smith & Nephew (ADR) | $26.94 | −2.04% | $11.55B | 18.8 | — | 1.8 | +4.6% |
| Solventum | $89.18 | +0.48% | $15.37B | 10.8 | 13.1 | 1.8 | +2.2% |
| AVITA Medical | $11.28 | −1.87% | $285.4M | — | — | 3.8 | +78.6% |
| TELA Bio | $1.43 | +1.42% | $63.1M | — | — | 0.8 | −4.5% |
| Median | 18.8 | 13.1 | 1.8 | +1.5% |